{"id":"W2911465702","doi":"10.1016/s1470-2045(18)30898-2","title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Foundation for Research on Metabolic Disorders; Cancer Research UK; Ironwood Pharmaceuticals, Incorporated; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Placebo; Quality of life (healthcare); Internal medicine; Discontinuation; Oncology; Prostate-specific antigen; Clinical trial; Visual analogue scale; Cancer; Physical therapy; Pathology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009537271,0.0003157331,0.001282379,0.0001547473,0.0001151518,0.00004588211,0.0001592576,0.0001005105,0.0003238755],"category_scores_gemma":[0.0001077617,0.0001526408,0.0001437855,0.0003867937,0.0001205381,0.000143195,0.0000559884,0.0004431431,0.00003590102],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006033505,"about_ca_system_score_gemma":0.001521657,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001047032,"about_ca_topic_score_gemma":0.002444776,"domain_scores_codex":[0.9972925,0.0002514926,0.0007028489,0.0004727552,0.0005219627,0.0007583961],"domain_scores_gemma":[0.998251,0.0006152921,0.0003404403,0.0005014346,0.0001292451,0.0001625885],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.938973,0.001124364,0.04681226,0.0001140956,0.001047353,0.001462246,0.003618716,0.0001075519,0.003582936,0.00001145604,0.0003044812,0.002841529],"study_design_scores_gemma":[0.984182,0.005262453,0.003833901,0.0001804166,0.0005358305,0.00003230719,0.001645804,0.0005212938,0.001896298,0.00001343477,0.00167603,0.0002202094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979082,0.0003054276,0.000005346682,0.003287716,0.0003547229,0.01370509,0.00003844891,0.00004795041,0.003173242],"genre_scores_gemma":[0.9907557,0.0002038571,0.0003906296,0.0004014333,0.0001464202,0.002851621,0.00008868319,0.0000445068,0.005117163],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04520901,"threshold_uncertainty_score":0.622451,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07290594750234178,"score_gpt":0.4120982191664367,"score_spread":0.3391922716640949,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}